首页 | 本学科首页   官方微博 | 高级检索  
     

胰岛素强化治疗在2型糖尿病患者中的疗效分析
引用本文:徐毅. 胰岛素强化治疗在2型糖尿病患者中的疗效分析[J]. 中国现代药物应用, 2011, 5(13): 20-21
作者姓名:徐毅
作者单位:贵阳医学院附属医院内分泌科,550004
摘    要:目的探讨胰岛素强化治疗在2型糖尿病患者中的临床效果。方法将我院收治的60例2型糖尿病患者,随机分为强化组1和强化组2,组1给予门冬胰岛素30治疗,组2给予门冬胰岛素联合甘精胰岛素治疗,比较两组血糖控制情况及不良反应发生情况。结果组1、组2治疗前后FPG、2hPG差异有统计学意义(P<0.05)。组2与组1治疗前、后FPG、2hPG差异无统计学意义(P>0.05)。组2血糖达标时间低于组1,差异有统计学意义(P<0.05)。组2胰岛素用量低于组1,差异有统计学意义(P<0.05)。结论 2型糖尿病患者用门冬胰岛素联合甘精胰岛素强化治疗与用门冬胰岛素30治疗相比,有效性相似,血糖达标快,胰岛素用量少,值得临床推广应用。

关 键 词:胰岛素强化  门冬胰岛素  甘精胰岛素  2型糖尿病

Curvative effect of insulin intensive treatment used in type 2 diabetes patients
XU Yi. Curvative effect of insulin intensive treatment used in type 2 diabetes patients[J]. Chinese Journal of Modern Drug Application, 2011, 5(13): 20-21
Authors:XU Yi
Affiliation:XU Yi. (Department of En- docrinology, The Affiliated Hospital of Guiyang Medical University, Guiyang 550004, China )
Abstract:Objective To discuss curvative effect of insulin intensive treatment used in type 2 diabetes patients. Methods Sixty type 2 diabetic patients were randomly diveded into two groups, observe group 1 and observe group 2, each group had thirty patients. Group 1 used aspart 30, Group 2 used aspart and glargine. The time when the blood glucose controlled, the amount of insulin and the adverse reaction were messured and noted. Results After treatment, both FPG and 2 hPG significantly decreased than before (P 〈 0.05 ), but there was no significant differences between two groups in those indexes ( P 〉 0.05 ). The time of glycemic control was shorter in group 2 than that in group 1. The dosage of insulin was less in group 2 than in group 1. Conclusion The intensive treatment with insulin detemir combined with Insulin Aspart is similar to that with aspart and glargine for type 2 diabetes patients on the efficacy, but is quicker in glycemic control, less in dosage of insulin. It is worth to ues in clinical.
Keywords:Insulin intensive treatment  Aspart insulin  Type 2 diabetes
本文献已被 CNKI 维普 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号